BNTC - NASDAQ

Benitec Biopharma Inc.

BNTC·NASDAQ

$10.70

+1.1%

HealthcareBiotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$280.84M

EPS-1.0500

P/E Ratio-10.19

Earnings Date09/28/2026

bntc

Retained Earnings

Last Annual Value

-228.18M

3-Year CAGR

-15%

5-Year CAGR

-14%

10-Year CAGR

-11%

Adjust for Inflation

Benitec Biopharma Inc. Competitors Analysis of Retained Earnings

BNTC · NASDAQ

Company	Retained Earnings	CAGR 3Y	CAGR 5Y	CAGR 10Y
Benitec Biopharma Inc. NASDAQ:BNTC	-228.18M	N/A	N/A	N/A
I-Mab NASDAQ:IMAB	-1.29B	N/A	N/A	N/A
Aura Biosciences, Inc. NASDAQ:AURA	-480.42M	N/A	N/A	N/A
DiaMedica Therapeutics Inc. NASDAQ:DMAC	-172.77M	N/A	N/A	N/A
Design Therapeutics, Inc. NASDAQ:DSGN	-297.01M	N/A	N/A	N/A
Humacyte, Inc. NASDAQ:HUMA	-726.85M	N/A	N/A	N/A
Korro Bio, Inc. NASDAQ:KRRO	-383.85M	N/A	N/A	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	-614.55M	N/A	N/A	N/A
Lineage Cell Therapeutics, Inc. AMEX:LCTX	-467.00M	N/A	N/A	N/A
PureTech Health plc NASDAQ:PRTC	61.27M	-9.9%	-21.1%	N/A
Galectin Therapeutics Inc. NASDAQ:GALT	-432.55M	N/A	N/A	N/A

Benitec Biopharma Inc. Fair Value Envelope

BNTC · NASDAQ

Our analysis suggests that BNTC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.7, this represents a potential HIDDEN relative to our calculated worth for Benitec Biopharma Inc..

HIDDEN

Intrinsic Value

Current Price: $10.7

Related Guides

Blog Categories

Continue your BNTC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.